Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGLEC7 | Q9Y286 | 4/20 | 0.57 |
| ▸ | MAG | P20916 | 5/20 | 0.57 |
| ▸ | CD22 | P20273 | 9/20 | 0.48 |
| ▸ | SELL | P14151 | 1/20 | 0.48 |
| ▸ | SELP | P16109 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14865175 | 0.88 | SIGLEC7 (0.57) | SIGLEC7MAGCD22SELLSELP | |
| SCHEMBL14819210 | 0.88 | SIGLEC7 (0.57) | SIGLEC7MAGCD22SELLSELP | |
| SCHEMBL16802876 | 0.88 | MAG (0.72) | SIGLEC7MAGCD22SELLSELP | |
| SCHEMBL17897325 | 0.87 | SIGLEC7 (0.66) | SIGLEC7MAGCD22SELLSELP | |
| SCHEMBL17889795 | 0.87 | SIGLEC7 (0.66) | SIGLEC7MAGCD22SELLSELP | |
| SCHEMBL29410578 | 0.87 | SIGLEC7 (0.55) | SIGLEC7MAGCD22SELLSELP | |
| SCHEMBL15177450 | 0.87 | SIGLEC7 (0.55) | SIGLEC7MAGCD22SELLSELP | |
| SCHEMBL29352702 | 0.87 | SIGLEC7 (0.55) | SIGLEC7MAGCD22SELLSELP | |
| SCHEMBL16298815 | 0.87 | SIGLEC7 (0.55) | SIGLEC7MAGCD22SELLSELP | |
| SCHEMBL29732933 | 0.87 | SIGLEC7 (0.55) | SIGLEC7MAGCD22SELLSELP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 779 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4704913-A2 | ANTIBODY-DRUG CONJUGATES EMPLOYING NOVEL LINKER-PAYLOAD SYSTEMS FOR ENHANCED TARGETING OF CANCER-ASSOCIATED ANTIGENS | BioNTech SE (DE) | 2026-03-11 | — | — | EP | claimed |
| EP-3645703-B1 | DETECTION AND ISOLATION OF CANCER CELLS FROM BODY FLUIDS BASED ON A GLYCOSYLATION PATTERN AND METHODS OF USE THEREOF | INSTITUTO DE PATOLOGIA E IMUNOLOGIA DA UNIV DO PORTO IPATIMUP (PT) | 2025-11-26 | — | — | EP | claimed |
| US-20250298012-A1 | METHODS AND KITS FOR QUANTIFYING GLYCOSYLATED ANALYTES | UNIOGEN OY (FI) | 2025-09-25 | — | — | US | claimed |
| US-20250258166-A1 | MEANS AND METHODS FOR HIGH-THROUGHPUT GLYCOPROFILING OF PROTEINS | GLYCANOSTICS S.R.O. (SK) | 2025-08-14 | — | — | US | claimed |
| US-20250223649-A1 | COMPOSITIONS AND METHODS FOR DETECTION OF LUNG CANCER | MERCY BIOANALYTICS, INC. | 2025-07-10 | — | — | US | claimed |
| EP-4543925-A1 | HUMANISED ANTIBODIES OR FUNCTIONAL FRAGMENTS THEREOF AGAINST TUMOUR ANTIGENS | BioNTech SE (DE) | 2025-04-30 | — | — | EP | claimed |
| EP-4536271-A2 | IMPROVED GLYCAN-DEPENDENT IMMUNOTHERAPEUTIC BI-SPECIFIC FUSION PROTEINS AND CHIMERIC ANTIGEN RECEPTORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-04-16 | — | — | EP | claimed |
| EP-4536282-A2 | IMPROVED GLYCAN-DEPENDENT CHIMERIC ANTIGEN RECEPTOR CELLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-04-16 | — | — | EP | claimed |
| US-20250108102-A1 | NOVEL FRAGMENTED CRS PEPTIDE EXHIBITING IMMUNE ENHANCEMENT ACTIVITY, AND USE THEREOF | ZYMEDI CO., LTD. (KR) | 2025-04-03 | — | — | US | claimed |
| WO-2025058008-A1 | ANTIBODY-DRUG CONJUGATE CONTAINING HETEROCYCLIC COMPOUND HAVING ACTIVITY OF INDUCING DECOMPOSITION OF G12D MUTANT KRAS PROTEIN | アステラス製薬株式会社 | 2025-03-20 | — | — | WO | claimed |
| WO-2022224241-A1 | CHIMERIC ANTIGEN RECEPTORS TO SIALYL-TN GLYCAN ANTIGEN | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2022-10-27 | — | — | WO | claimed |
| US-20220306727-A1 | Methods of Purifying Masked Antibodies | SEAGEN INC. (US) | 2022-09-29 | — | — | US | claimed |
| CN-115003330-A | Novel glycoconjugates as vaccines and diagnostic tools | 科纳克斯资本 | 2022-09-02 | — | — | CN | claimed |
| WO-2022175390-A1 | POLYSACCHARIDE COMPLEX | ACARYON GMBH (DE) | 2022-08-25 | — | — | WO | claimed |
| US-11401330-B2 | Glycan-interacting compounds and methods of use | SEAGEN INC. (US) | 2022-08-02 | — | — | US | claimed |
| US-20220233709-A1 | Masked Antibody Formulations | SEAGEN INC. (US) | 2022-07-28 | — | — | US | claimed |
| EP-4031252-A2 | MULTIMERIC ANTIBODIES WITH ENHANCED SELECTIVITY FOR CELLS WITH HIGH TARGET DENSITY | IGM Biosciences, Inc. (US) | 2022-07-27 | — | — | EP | claimed |
| EP-4013792-A1 | IMMUNOSTIMULATORY MULTIMERIC BINDING MOLECULES | IGM Biosciences Inc. (US) | 2022-06-22 | — | — | EP | claimed |
| WO-2022124849-A1 | NOVEL FRAGMENTED CRS PEPTIDE EXHIBITING IMMUNE ENHANCEMENT ACTIVITY, AND USE THEREOF | 재단법인 의약바이오컨버젼스연구단 | 2022-06-16 | — | — | WO | claimed |
| US-11235064-B2 | Core constructs and their uses in configuring pharmaceutical molecules | Immunwork Inc. (TW) | 2022-02-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11235064-B2 | Core constructs and their uses in configuring pharmaceutical molecules | PAICS, QPCT, GP6 | SIGLEC7 227/4885MAG 517/4885CD22 1561/4885 |
| US-20220306727-A1 | Methods of Purifying Masked Antibodies | CD47, ITGA5, FCGRT | SIGLEC7 81/4885MAG 254/4885CD22 36/4885 |
| US-20220233709-A1 | Masked Antibody Formulations | CD47, FCGRT, TTR | SIGLEC7 136/4885MAG 61/4885CD22 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.